Instrument Inactif

Communiqués Lannett Company, Inc.

Actions

LCI

US5160122009

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

LANNETT COMPANY, INC. FILES PREPACKAGED CHAPTER 11 CASES TO SIGNIFICANTLY STRENGTHEN FINANCIAL POSITION	03/05/23	PR
Lannett Company, Inc. Enters Into Restructuring Support Agreement	01/05/23	PR
NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS	20/04/23	PR
LANNETT CO INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	14/04/23	AQ
LANNETT CO INC : Other Events, Financial Statements and Exhibits (form 8-K)	04/04/23	AQ
LANNETT SHARES UPDATE	04/04/23	PR
Lannett : Modification to Rights of Security Holders - Form 8-K	07/02/23	PU
LANNETT CO INC : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	07/02/23	AQ
LANNETT CO INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	02/02/23	AQ
LANNETT CO INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	02/02/23	AQ
Lannett: Fiscal Q2 Earnings Snapshot	01/02/23	AQ
LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE	01/02/23	PR
Lannett : Submission of Matters to a Vote of Security Holders - Form 8-K	26/01/23	PU
LANNETT CO INC : Submission of Matters to a Vote of Security Holders (form 8-K)	26/01/23	AQ
LANNETT ANNOUNCES 1 FOR 4 REVERSE STOCK SPLIT	25/01/23	PR
LANNETT TO REPORT FISCAL 2023 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, FEBRUARY 1	25/01/23	PR
LANNETT PROVIDES DEVELOPMENT UPDATE ON BIOSIMILAR INSULIN PRODUCTS	04/01/23	PR
LANNETT CO INC : Costs Associated with Exit or Disposal Activities, Material Impairments (form 8-K)	16/12/22	AQ
LANNETT CO INC : Entry into a Material Definitive Agreement (form 8-K)	14/11/22	AQ
LANNETT ANNOUNCES PATENT LICENSES FOR THE PEN INJECTOR DELIVERY DEVICE TO BE USED FOR ITS INSULIN GLARGINE AND INSULIN ASPART DEVELOPMENT PROGRAM	07/11/22	PR

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Lannett Company, Inc.

Actions

LCI

US5160122009

Communiqués

Filtres